Login Register
icon_bulk_orderBulk order Acrobiosystems for ChineseChinese
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
SARS-CoV-2  lambda  Delta | Claudin 18.2 | CD20 | CD3 | FcR | IL-2R
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-3 R alpha

IL-3 R alpha

Brief Information

Name:Interleukin-3 receptor subunit alpha
Target Synonym:Interleukin-3 Receptor Subunit Alpha,Interleukin-3 Receptor alpha Subunit,IL3RY,IL3RX,IL-3R Subunit Alpha,CD123 Antigen,IL-3RA,IL-3 Receptor Alpha SP2 Isoform,Interleukin 3 Receptor Subunit Alpha,IL3RAY,IL3R,IL-3 Receptor Subunit Alpha,HIL-3Ra,Interleukin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ILA-H82F3 Human Biotinylated Human IL-3 R alpha / CD123 Protein, Fc,Avitag™ (MALS verified)
ILA-H82F3-structure
ILA-H82F3-sds
ILA-H82F3-elisa_1
ILA-HF253 Human FITC-Labeled Human IL-3 R alpha / CD123 Protein, Fc Tag
ILA-HF253-structure
ILA-HF253-sds
ILA-HF253-elisa_1
ILA-H5252 Human Human IL-3 R alpha / CD123 Protein, Fc Tag (MALS & SPR verified)
ILA-H5252-structure
ILA-H5252-sds
ILA-H5252-elisa_2
ILA-C52H3 Canine Canine IL-3 R alpha / CD123 Protein, His Tag
ILA-C52H3-structure
ILA-C52H3-sds
ILA-H82H5 Human Biotinylated Human IL-3 R alpha / CD123 Protein, His,Avitag™ (MALS verified)
ILA-H82H5-structure
ILA-H82H5-sds
ILA-H82H5-elisa_1
ILA-HF2H9 Human FITC-Labeled Human IL-3 R alpha / CD123 Protein, His Tag
ILA-HF2H9-structure
ILA-HF2H9-sds
ILA-M52H4 Mouse Mouse IL-3 R alpha / CD123 Protein, His Tag (SPR verified)
ILA-M52H4-structure
ILA-M52H4-sds
ILA-M52H4-elisa_2
ILA-C52H6 Cynomolgus Cynomolgus IL-3 R alpha / CD123 Protein, His Tag (SPR verified)
ILA-C52H6-structure
ILA-C52H6-sds
ILA-C52H6-elisa_2
ILA-H5255 Human Human IL-3 R alpha / CD123 Protein, Llama IgG2b Fc Tag, low endotoxin
ILA-H5255-structure
ILA-H5255-sds
ILA-H52H6 Human Human IL-3 R alpha / CD123 Protein, His Tag (MALS & SPR verified)
ILA-H52H6-structure
ILA-H52H6-sds
ILA-H52H6-elisa_2

Part of Bioactivity data

ILA-H5252-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol
ILA-M52H4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Mouse IL-3 R alpha, His Tag (Cat. No. ILA-M52H4) captured on CM5 Chip via anti-His antibody can bind Mouse IL-3, Tag Free with an affinity constant of 0.704 μM as determined in SPR assay (Biacore T200) (QC tested).

Protocol

Synonym Name

IL3R,IL3RA,IL-3Ra,IL-3R-alpha,IL3RAY,IL3RX,IL3RY,CD123 antigen,CD123,hIL3Ra,hIL-3Ra,MGC34174,IL-3 R alpha

Background

Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tagraxofusp DTIL-3; SL-401; DT388 IL3 Approved Texas A&M University Development Foundation Elzonris EU Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma Stemline Therapeutics Inc 2018-12-21 Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KHK-2823 KHK-2823 Phase 1 Clinical Kyowa Hakko Kirin Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan Union Hospital Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Southwest Hospital) Phase 2 Clinical Southwest Hospital Chongqing Leukemia, Myeloid Details
CD123 CAR-T cells (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
UniCAR-T-CD-123 UniCAR-T-CD123 Phase 1 Clinical Gemoab Monoclonals Gmbh Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
APVO436 APVO-436 Phase 1 Clinical Aptevo Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute Details
CD123 CAR-T cell therapy Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia, Myeloid; Leukemia; Leukemia, Myeloid, Acute Details
Flotetuzumab MGD-006; S-80880 Phase 2 Clinical Macrogenics Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia, Myeloid, Acute Details
Anti-CD123 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
JNJ-63709178 JNJ-9178; CNTO-9958; JNJ-63709178 Phase 1 Clinical Janssen Global Services Llc, Genmab Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
CSL-360 IL-3Rα; CSL-360 Phase 1 Clinical Csl Ltd Leukemia, Myeloid, Acute Details
Talacotuzumab CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL Phase 3 Clinical Csl Ltd Myelodysplastic Syndromes; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute Details
Vibecotamab XmAb-14045 Phase 1 Clinical Xencor Hematologic Neoplasms; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
IMGN-632 IMGN-632 Phase 2 Clinical Immunogen Myeloproliferative Disorders; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
MB-102 (Mustang Bio) MB-102 Phase 2 Clinical Mustang Bio, City Of Hope National Medical Center Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
UCART-123 UCART-123 Phase 1 Clinical Cellectis Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
UniCAR02-T UniCAR02-T Phase 1 Clinical Cellex Patient Treatment Gmbh Kidney Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap